drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An IgG-based bispecific T-cell–engaging antibody that binds CD276 (B7-H3) on tumor and tumor vasculature and CD3 on T cells; includes an attenuated CD3 binder and YTE Fc modification to extend half-life, designed to redirect T cells to CD276+ targets and provide anti-angiogenic effects.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
IgG-based bispecific antibody that binds CD276 (B7-H3) on tumor and tumor vasculature and CD3 on T cells to redirect and activate T cells for cytotoxic killing of CD276+ targets; incorporates an attenuated CD3 binder to reduce off-target activation/CRS risk and a YTE Fc modification to extend half-life, with potential anti-angiogenic effects via CD276 on tumor endothelium.
drug_name
CC-3
nct_id_drug_ref
NCT05999396